Ironwood Pharmaceuticals Statistics
Share Statistics
Ironwood Pharmaceuticals has 160.03M shares outstanding. The number of shares has increased by 2.24% in one year.
| Shares Outstanding | 160.03M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.18% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 155.77M |
| Failed to Deliver (FTD) Shares | 1.05K |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 12.08M, so 7.55% of the outstanding shares have been sold short.
| Short Interest | 12.08M |
| Short % of Shares Out | 7.55% |
| Short % of Float | 7.76% |
| Short Ratio (days to cover) | 6.67 |
Valuation Ratios
The PE ratio is -1.77 and the forward PE ratio is 11.57.
| PE Ratio | -1.77 |
| Forward PE | 11.57 |
| PS Ratio | 4.02 |
| Forward PS | 1.4 |
| PB Ratio | -5.13 |
| P/FCF Ratio | 9.71 |
| PEG Ratio | n/a |
Enterprise Valuation
Ironwood Pharmaceuticals Inc. has an Enterprise Value (EV) of 2.40B.
| EV / Earnings | -2.4 |
| EV / Sales | 5.42 |
| EV / EBITDA | -2.6 |
| EV / EBIT | -2.54 |
| EV / FCF | 13.11 |
Financial Position
The company has a current ratio of 0.84, with a Debt / Equity ratio of -2.02.
| Current Ratio | 0.84 |
| Quick Ratio | 0.84 |
| Debt / Equity | -2.02 |
| Total Debt / Capitalization | 198.5 |
| Cash Flow / Debt | 0.26 |
| Interest Coverage | -43.71 |
Financial Efficiency
Return on equity (ROE) is 2.89% and return on capital (ROIC) is -278.59%.
| Return on Equity (ROE) | 2.89% |
| Return on Assets (ROA) | -2.13% |
| Return on Capital (ROIC) | -278.59% |
| Revenue Per Employee | 1.66M |
| Profits Per Employee | -3.75M |
| Employee Count | 267 |
| Asset Turnover | 0.94 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 83.49M |
| Effective Tax Rate | -0.09 |
Stock Price Statistics
The stock price has increased by -68.91% in the last 52 weeks. The beta is 0.47, so Ironwood Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.47 |
| 52-Week Price Change | -68.91% |
| 50-Day Moving Average | 4.02 |
| 200-Day Moving Average | 5.46 |
| Relative Strength Index (RSI) | 39.1 |
| Average Volume (20 Days) | 1.90M |
Income Statement
In the last 12 months, Ironwood Pharmaceuticals had revenue of 442.74M and earned -1.00B in profits. Earnings per share was -6.45.
| Revenue | 442.74M |
| Gross Profit | 337.95M |
| Operating Income | -945.43M |
| Net Income | -1.00B |
| EBITDA | -924.86M |
| EBIT | -945.43M |
| Earnings Per Share (EPS) | -6.45 |
Balance Sheet
The company has 92.15M in cash and 715.54M in debt, giving a net cash position of -623.38M.
| Cash & Cash Equivalents | 92.15M |
| Total Debt | 715.54M |
| Net Cash | -623.38M |
| Retained Earnings | -1.70B |
| Total Assets | 389.52M |
| Working Capital | 129.22M |
Cash Flow
In the last 12 months, operating cash flow was 183.43M and capital expenditures -273.00K, giving a free cash flow of 183.15M.
| Operating Cash Flow | 183.43M |
| Capital Expenditures | -273.00K |
| Free Cash Flow | 183.15M |
| FCF Per Share | 1.18 |
Margins
Gross margin is 76.33%, with operating and profit margins of -213.54% and -226.37%.
| Gross Margin | 76.33% |
| Operating Margin | -213.54% |
| Pretax Margin | -214.14% |
| Profit Margin | -226.37% |
| EBITDA Margin | -208.9% |
| EBIT Margin | -213.54% |
| FCF Margin | 41.37% |
Dividends & Yields
IRWD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -176.71% |
| FCF Yield | 31.31% |
Analyst Forecast
The average price target for IRWD is $11, which is 201.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $11 |
| Price Target Difference | 201.4% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Apr 2, 2019. It was a forward split with a ratio of 597:500.
| Last Split Date | Apr 2, 2019 |
| Split Type | forward |
| Split Ratio | 597:500 |
Scores
| Altman Z-Score | -3.23 |
| Piotroski F-Score | 7 |